Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: anti-Mycobacterium tuberculosis activity and cytotoxicity. 2010

Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
Faculdade de CiĂȘncias FarmacĂȘuticas, Universidade Estadual Paulista, 14801-902 Araraquara, SP, Brazil. pavanfer@yahoo.com.br

The aim of this study was to identify a candidate drug for the development of anti-tuberculosis therapy from previously synthesized compounds based on the thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones compounds. The minimal inhibitory concentration (MIC) of these compounds against Mycobacterium tuberculosis was determined. Their in vitro cytotoxicity to J774 cells (IC50) was determined to establish a selectivity index (SI) (SI=IC50/MIC). The best compounds were the thiosemicarbazones (2, 3 and 4) and the hydrazide/hydrazones (14, 15, 16 and 18). The results are comparable to or better than those of "first line" or "second line" drugs commonly used to treat TB, suggesting these compounds as anti-TB drug candidates.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012664 Semicarbazones A class of organic compounds that are derivatives of imines formed by condensation reactions between KETONES or ALDEHYDES and SEMICARBAZIDES. Semicarbazone
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
September 1975, Il Farmaco; edizione scientifica,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
June 2011, ChemMedChem,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
February 2016, Bioorganic & medicinal chemistry letters,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
July 2020, Bioorganic & medicinal chemistry,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
November 1967, Journal of medicinal chemistry,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
February 1995, Anti-cancer drugs,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
December 2019, Natural product research,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
January 2022, Journal of biomolecular structure & dynamics,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
December 2011, Experimental parasitology,
Fernando R Pavan, and Pedro I da S Maia, and Sergio R A Leite, and Victor M Deflon, and Alzir A Batista, and Daisy N Sato, and Scott G Franzblau, and Clarice Q F Leite
October 2000, Indian journal of physiology and pharmacology,
Copied contents to your clipboard!